自发性颈部动脉夹层的抗凝与抗血小板治疗比较:系统综述与荟萃分析
该系统综述与荟萃分析纳入11项研究共5039例颈部动脉夹层患者,比较抗凝与抗血小板治疗。抗凝治疗与较低的缺血性卒中风险相关(RR 0.63,95%CI 0.43-0.94),但大出血风险较高(RR 2.25,95%CI 1.07-4.72),死亡和症状性颅内出血风险相似。作者认为应采取个体化治疗策略。
要点
- 抗凝治疗与缺血性卒中风险降低相关(RR 0.63,95%CI 0.43-0.94;P=0.02;I²=0%)。
- 抗凝治疗与大出血风险升高相关(RR 2.25,95%CI 1.07-4.72;P=0.03;I²=0%)。
- 死亡和症状性颅内出血风险在两种治疗间相似。
核心结论
- 在颈部动脉夹层患者中,抗凝在降低缺血性卒中方面优于抗血小板治疗,但大出血风险更高。
- 作者认为这支持采取个体化治疗策略,综合权衡缺血性卒中减少的净临床获益与出血风险。
- 需要大型随机临床试验来明确颈部动脉夹层的最佳抗血栓策略。
研究设计与样本
- 系统综述与荟萃分析,已在PROSPERO注册(CRD42023468063)。
- 检索5个数据库,纳入相关随机试验和与重大创伤无关的夹层观察性研究。
- 共纳入11项研究(2项随机试验和9项观察性研究),5039例患者,其中30%(1512例)接受抗凝治疗,70%(3527例)接受抗血小板治疗。
主要发现
- 抗凝治疗与较低的缺血性卒中风险相关(相对风险0.63,95%CI 0.43-0.94;P=0.02;I²=0%)。
- 抗凝治疗与较高的大出血风险相关(相对风险2.25,95%CI 1.07-4.72;P=0.03;I²=0%)。
- 死亡和症状性颅内出血风险在两种治疗间相似。
- 随机试验中的效应量更大。
- 关于双联抗血小板治疗或直接口服抗凝药的有效性和安全性数据不足。
临床怎么用
- 作者认为这支持采取个体化治疗策略,综合权衡缺血性卒中减少的净临床获益与出血风险。
- 需要大型随机临床试验来明确颈部动脉夹层的最佳抗血栓策略。
局限性
- 关于双联抗血小板治疗或直接口服抗凝药的有效性和安全性数据不足。
- 需要大型随机临床试验来明确颈部动脉夹层的最佳抗血栓策略。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: It is uncertain whether antiplatelets or anticoagulants are more effective in preventing early recurrent stroke in patients with cervical artery dissection. Following the publication of the observational Antithrombotic for STOP-CAD (Stroke Prevention in Cervical Artery Dissection) study, which has more than doubled available data, we performed an updated systematic review and meta-analysis comparing antiplatelets versus anticoagulation in cervical artery dissection. METHODS: The systematic review was registered in PROSPERO (CRD42023468063). We searched 5 databases using a combination of keywords that encompass different antiplatelets and anticoagulants, as well as cervical artery dissection. We included relevant randomized trials and included observational studies of dissection unrelated to major trauma. Where studies were sufficiently similar, we performed meta-analyses for efficacy (ischemic stroke) and safety (major hemorrhage, symptomatic intracranial hemorrhage, and death) outcomes using relative risks. RESULTS: We identified 11 studies (2 randomized trials and 9 observational studies) that met the inclusion criteria. These included 5039 patients (30% [1512] treated with anticoagulation and 70% [3527]) treated with antiplatelets]. In meta-analysis, anticoagulation was associated with a lower ischemic stroke risk (relative risk, 0.63 [95% CI, 0.43 to 0.94]; P=0.02; I2=0%) but higher major bleeding risk (relative risk, 2.25 [95% CI, 1.07 to 4.72]; P=0.03, I2=0%). The risks of death and symptomatic intracranial hemorrhage were similar between the 2 treatments. Effect sizes were larger in randomized trials. There are insufficient data on the efficacy and safety of dual antiplatelet therapy or direct oral anticoagulants. CONCLUSIONS: In this study of patients with cervical artery dissection, anticoagulation was superior to antiplatelet therapy in reducing ischemic stroke but carried a higher major bleeding risk. This argues for an individualized therapeutic approach incorporating the net clinical benefit of ischemic stroke reduction and bleeding risks. Large randomized clinical trials are required to clarify optimal antithrombotic strategies for management of cervical artery dissection.
引用
- Yaghi S, Shu L, Fletcher L, et al. Anticoagulation Versus Antiplatelets in Spontaneous Cervical Artery Dissection: A Systematic Review and Meta-Analysis. Stroke. 2024. PMID: 38847098. doi:10.1161/STROKEAHA.124.047310
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。